[A24-106] Vadadustat (symptomatic anaemia associated with dialysis-dependent chronic kidney disease) – Addendum to Project A24-67
Last updated 22.11.2024
Project no.:
A24-106
Commission:
Commission awarded on 08.10.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Therapeutic indication: Adult patients with symptomatic anaemia associated with chronic kidney disease who are on chronic maintenance dialysis
Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A24-106_en
| Project no. | Title | Status |
|---|---|---|
| A24-67 | Vadadustat (anaemia associated with chronic kidney disease on dialysis) – Benefit assessment according to § 35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-11-22 A G-BA decision was published.